91. Deputy Gino Kenny asked the Minister for Health his plans to use a drug approval and reimbursement system for MS drugs similar to that in Germany (details supplied); and if he will make a statement on the matter. (Question 16408/18 asked on 19 Apr 2018 - Medicinal Products Reimbursement)

Minister for Health (Deputy Simon Harris): The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. As Minister for Health, I do not have any statutory power or function in relation to the reimbursement of medicines. The Act specifies the criteria for decisions on the reimbursement of medicines.
In line with the 2013 Act, if a company would like a medicine to be reimbursed by the HSE pur...

51. Deputy Gino Kenny asked the Minister for Health the likely timescale of the conclusion of HSE negotiations with the manufacturer of the drug Kuvan; his views on the urgency of it being made available for persons with PKU here; and if he will make a statement on the matter. (Question 48174/17 asked on 15 Nov 2017 - Medicinal Products Reimbursement)

Minister for Health (Deputy Simon Harris): I propose to take Questions Nos. 49 and 51 together.
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
In reaching a decision, the HSE examines all the evidence which may be relevant in its view for the decision and will take into account such expert opinions and recommendations which may have been so...

59. Deputy Gino Kenny asked the Minister for Health the circumstances in which the drug, Vimizin, a treatment for those that suffer from the rare disease Morquio, has been refused funding by the HSE; and if he will make a statement on the matter. (Question 40922/17 asked on 28 Sep 2017 - Medicinal Products Reimbursement)

Minister for Health (Deputy Simon Harris): The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE issued a Notice of Proposal not to support reimbursement of Elosulfase alfa (Vimizim) to the manufacturer BioMarin in June 2017.
The Health (Pricing and Supply of Medical Goods) Act 2013 allows suppliers at least 28 days in wh...

180. Deputy Gino Kenny asked the Minister for Health if his attention has been drawn to the fact that prescribed low protein foods are required to prevent neurological damage and to supplement the diet of adults and children with phenylketonuria, PKU; if his attention has further been drawn to the fact that no new low protein products have been added to the long-term illness card list in more than six years; if he will ensure a full and appropriate updated list of foods prescribed for PKU is added to the reimbursement list; and if he will make a statement on the matter. (Question 36618/16 asked on 24 Nov 2016 - Medicinal Products Reimbursement)

Minister for Health (Deputy Simon Harris): I propose to take Questions Nos. 177 and 180 together.
The HSE has statutory responsibility for decisions on pricing and reimbursement of products under the community drug schemes, including the LTI Scheme, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy. 
 ...